Home Newsfeeds Macquarie Upgrades New Oriental Education to Outperform

Macquarie Upgrades New Oriental Education to Outperform

Macquarie analyst Linda Huang upgrades New Oriental Education (NYSE:EDU) from Neutral to Outperform.

byBenzinga Newsdesk

July 28, 2022

1 minute read

Macquarie analyst Linda Huang upgrades New Oriental Education (NYSE:EDU) from Neutral to Outperform.

Needham Reiterates Buy on SentinelOne, Maintains $19 Price Target

By Benzinga Newsdesk

March 15, 6:55 AM

Needham analyst Alex Henderson reiterates SentinelOne (NYSE:S) with a Buy and maintains $19 price target.

Trump SPAC Merger Deal Includes Provisions For ‘Material Disruptive Events’ Like A Presidential Run And Prison Time

By Chris Katje

August 24, 1:25 PM

One of the most talked about SPAC mergers of all time saw shares surge in valuation and demand and brought interest back to the SPAC market. A filing shows some provisions for the SPAC merger based on its well-known namesake leader.

DIS

Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus

By Benzinga Newsdesk

April 4, 4:01 PM

-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety and efficacy

CRBU

P.A.M. Transportation Q4 EPS $1.08 Beats $0.80 Estimate, Sales $203.45M Miss $238.70M Estimate

By Happy Mohamed

February 13, 5:46 PM

P.A.M. Transportation (NASDAQ:PTSI) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $0.80 by 35 percent. This is a 24.48 percent decrease over earnings of $1.43 per share from

PTSI

Macquarie Upgrades New Oriental Education to Outperform

Related Posts

Needham Reiterates Buy on SentinelOne, Maintains $19 Price Target

Trump SPAC Merger Deal Includes Provisions For ‘Material Disruptive Events’ Like A Presidential Run And Prison Time

Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus

P.A.M. Transportation Q4 EPS $1.08 Beats $0.80 Estimate, Sales $203.45M Miss $238.70M Estimate